WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25

A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen ($949.37 million) loss for the fiscal year.  | The company adjusted its full-year 2025 earnings to account for a legal provision of 402.5 billion JPY ($2.5 billion).

Raccontata dafiercepharma.comendpoints.news

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
fiercepharma.comStai leggendo6 g fa

Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25

A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen ($949.37 million) loss for the fiscal year.  | The company adjusted its full-year 2025…

originale
endpoints.news4 g fa

Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal

Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza.

Leggi questa versione → originale

Timeline cronologica

  1. venerdì 5 giugno 2026·fiercepharma.com

    Takeda takes $2.5B legal charge after pay-for-delay verdict, swings to loss for '25

    A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen ($949.37 million) loss for the fiscal year.  |…

  2. lunedì 8 giugno 2026·endpoints.news

    Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appeal

    Takeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza.